Vir Bio Stock (NASDAQ:VIR)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$6.93

52W Range

$6.62 - $13.09

50D Avg

$7.99

200D Avg

$9.19

Market Cap

$928.23M

Avg Vol (3M)

$961.67K

Beta

0.46

Div Yield

-

VIR Company Profile


Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

587

IPO Date

Oct 11, 2019

Website

VIR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Contract Revenue$2.23M$52.71M$169.87M
Collaboration Revenue$37.27M$1.51B$917.19M
License Revenue---
Grant$46.69M--
License-$22.29M-

Fiscal year ends in Dec 23 | Currency in USD

VIR Financial Summary


Dec 23Dec 22Dec 21
Revenue$86.18M$1.58B$1.09B
Operating Income$-684.30M$833.07M$276.89M
Net Income$-615.06M$515.84M$528.58M
EBITDA$-684.30M$944.21M$282.70M
Basic EPS-$3.89$4.07
Diluted EPS-$3.83$3.96

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 31, 24 | 11:12 PM
Q2 24Aug 01, 24 | 10:10 PM
Q1 24May 02, 24 | 12:00 AM

Peer Comparison


TickerCompany
AKROAkero Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
CVACCureVac N.V.
TERNTerns Pharmaceuticals, Inc.
VKTXViking Therapeutics, Inc.
KRYSKrystal Biotech, Inc.
KRTXKaruna Therapeutics, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.